Septerna, Inc. (NASDAQ:SEPN - Get Free Report) reached a new 52-week low during trading on Monday . The stock traded as low as $12.17 and last traded at $11.88, with a volume of 12510 shares. The stock had previously closed at $13.09.
Analyst Upgrades and Downgrades
Several research analysts have recently issued reports on the stock. TD Cowen assumed coverage on shares of Septerna in a report on Tuesday, November 19th. They issued a "buy" rating for the company. JPMorgan Chase & Co. assumed coverage on shares of Septerna in a report on Tuesday, November 19th. They issued an "overweight" rating and a $38.00 target price for the company. Cantor Fitzgerald restated an "overweight" rating and issued a $50.00 target price on shares of Septerna in a report on Tuesday. Finally, Wells Fargo & Company began coverage on shares of Septerna in a research report on Tuesday, November 19th. They issued an "overweight" rating and a $43.00 price target for the company.
Get Our Latest Analysis on SEPN
Septerna Stock Performance
The firm has a fifty day moving average price of $19.60.
Institutional Trading of Septerna
A number of hedge funds have recently made changes to their positions in SEPN. New York State Common Retirement Fund acquired a new stake in shares of Septerna during the fourth quarter worth approximately $32,000. Legal & General Group Plc acquired a new position in Septerna in the fourth quarter worth $42,000. Ameritas Investment Partners Inc. acquired a new position in Septerna in the fourth quarter worth $45,000. PNC Financial Services Group Inc. acquired a new position in Septerna in the fourth quarter worth $61,000. Finally, SG Americas Securities LLC acquired a new position in shares of Septerna during the fourth quarter valued at $185,000.
Septerna Company Profile
(
Get Free Report)
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.
Read More
Before you consider Septerna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Septerna wasn't on the list.
While Septerna currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
